Addex Therapeutics Ltd
ADXN8.849USD
+0.749+9.24%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
7.25MMarktkapitalisierung
0.96KGV TTM
mehr Informationen über Addex Therapeutics Ltd Unternehmen
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Unternehmensinformationen
BörsenkürzelADXN
Name des UnternehmensAddex Therapeutics Ltd
IPO-datumMay 22, 2007
CEOMr. Tim Dyer
Anzahl der mitarbeiter2
WertpapierartOrdinary Share
GeschäftsjahresendeMay 22
AddresseChemin des Mines, 9
StadtPLAN-LES-OUATES
BörseSIX Swiss Exchange
LandSwitzerland
Postleitzahl1202
Telefon41228841555
Websitehttps://www.addextherapeutics.com/en/
BörsenkürzelADXN
IPO-datumMay 22, 2007
CEOMr. Tim Dyer
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Mikhail Kalinichev
Dr. Mikhail Kalinichev
Member of the Executive Management, Head of Translational Science
Member of the Executive Management, Head of Translational Science
--
--
Dr. Raymond G. (Ray) Hill
Dr. Raymond G. (Ray) Hill
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Mr. Lenaic Teyssedou
Mr. Lenaic Teyssedou
Member of the Executive Management, Head of Finance
Member of the Executive Management, Head of Finance
--
--
Dr. Vincent Lawton
Dr. Vincent Lawton
Independent Non-Executive Chairman of the Board of Directors
Independent Non-Executive Chairman of the Board of Directors
--
--
Mr. Jake R. Nunn
Mr. Jake R. Nunn
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Mr. Tim Dyer
Mr. Tim Dyer
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
--
--
Dr. Isaac Manke
Dr. Isaac Manke
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Dr. Roger G. Mills
Dr. Roger G. Mills
Member of the Executive Management, Chief Medical Officer, Member of the Board of Directors
Member of the Executive Management, Chief Medical Officer, Member of the Board of Directors
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Mikhail Kalinichev
Dr. Mikhail Kalinichev
Member of the Executive Management, Head of Translational Science
Member of the Executive Management, Head of Translational Science
--
--
Dr. Raymond G. (Ray) Hill
Dr. Raymond G. (Ray) Hill
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Mr. Lenaic Teyssedou
Mr. Lenaic Teyssedou
Member of the Executive Management, Head of Finance
Member of the Executive Management, Head of Finance
--
--
Dr. Vincent Lawton
Dr. Vincent Lawton
Independent Non-Executive Chairman of the Board of Directors
Independent Non-Executive Chairman of the Board of Directors
--
--
Mr. Jake R. Nunn
Mr. Jake R. Nunn
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Mr. Tim Dyer
Mr. Tim Dyer
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sun, Feb 23
Aktualisiert: Sun, Feb 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Citadel Advisors LLC
1.10%
GAMMA Investing LLC
0.01%
Other
98.89%
Aktionäre
Aktionäre
Anteil
Citadel Advisors LLC
1.10%
GAMMA Investing LLC
0.01%
Other
98.89%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
1.10%
Investment Advisor/Hedge Fund
0.01%
Other
98.89%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
12
12.04K
1.13%
-165.56K
2025Q1
16
13.11K
1.23%
-176.53K
2024Q4
17
15.10K
1.41%
-160.92K
2024Q3
22
37.43K
5.74%
-146.56K
2024Q2
21
38.45K
5.90%
-143.53K
2024Q1
20
36.44K
5.64%
-145.16K
2023Q4
19
195.87K
20.93%
+138.26K
2023Q3
18
73.39K
96.72%
+38.94K
2023Q2
18
50.23K
7.45%
-253.79K
2023Q1
17
333.00K
49.67%
+248.23K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Citadel Advisors LLC
11.74K
1.1%
-338.00
-2.80%
Mar 31, 2025
GAMMA Investing LLC
1.19K
0.11%
+182.00
+18.00%
Mar 31, 2025
Morgan Stanley & Co. LLC
100.00
0.01%
-1.80K
-94.74%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
72.00
0.01%
-35.00
-32.71%
Mar 31, 2025
SBI Securities Co., Ltd.
5.00
0%
--
--
Mar 31, 2025
J. Stern & Co. LLP
--
0%
-107.83K
-100.00%
Mar 31, 2024
Armistice Capital LLC
--
0%
-43.00K
-100.00%
Mar 31, 2024
Baader Bank AG
--
0%
-960.00
-100.00%
Dec 31, 2023
Jane Street Capital, L.L.C.
--
0%
-529.00
-100.00%
Dec 31, 2023
New Enterprise Associates (NEA)
--
0%
-9.00K
-100.00%
Mar 31, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Oct 06, 2023
Merger
20<1
Oct 06, 2023
Merger
20<1
Oct 06, 2023
Merger
20<1
Oct 06, 2023
Merger
20<1
Datum
Art
Verhältnis
Oct 06, 2023
Merger
20<1
Oct 06, 2023
Merger
20<1
Oct 06, 2023
Merger
20<1
Oct 06, 2023
Merger
20<1
